Mererid Evans

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna, Max Robinson, A. Hartley et al. · The Lancet · 2018 · 1K citations · Full text

Medicine, Oncology, Radiation Oncology +12

Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines

Vincent Grégoire, Mererid Evans, Quynh‐Thu Le et al. · Radiotherapy and Oncology · 2017 · 405 citations · Full text

Medicine, Oncology, Radiation Oncology +17

PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer

Waheeda Owadally, Chris Hurt, Hayley Timmins et al. · BMC Cancer · 2015 · 263 citations · Full text

Medicine, Oncology, Oral Surgery +17

HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology

Andrew Schache, Ned Powell, Kate Cuschieri et al. · Cancer Research · 2016 · 212 citations · Full text

Medicine, Oncology, Cancer Epidemiology +13